#160942

RLUN012-2 Lung cancer organoid

Cat. #160942

RLUN012-2 Lung cancer organoid

Cat. #: 160942

Sub-type: Organoids

Unit size: 40-100 uL of cell pellet/vial, 1ml

Availability: 8-10 weeks

Organism: Human

Tissue: Lung

£2,500.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Medical-Industrial Translational Research Center

Institute: Fukushima Medical University

Tool Details
Handling
Application Details
Documentation

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Tool name: RLUN012-2 Lung cancer organoid
  • Alternate name: RLUN012-2, RLUN12-2, RLUN12, RLUN012
  • Cancer: Lung cancer
  • Cancers detailed: Lung;Papillary adenocarcinoma
  • Age y o : 74
  • Research fields: Cancer
  • Tool sub type: Organoids
  • Organism: Human
  • Tissue: Lung
  • Gender: Male
  • Growth properties: Suspension
  • Application: 3D cell culture, High-throughput screening
  • Description: A series of novel patient-derived organoids (PDOs) have been constructed from different tumor tissue types under the Fukushima Translational Research Project, designated as F-PDO. F-PDOs form large cell clusters with a morphology similar to the original tumor and can be cultured for more than six months. Our comparative histological and comprehensive gene expression analyses have shown that the characteristics of F-PDOs were similar to their source tumors, even after long-term growth in culture conditions
  • Biosafety level: 2

Handling

  • Format: Frozen
  • Passage number: 5
  • Growth medium: Cancer Cell Expansion Media plus (Fujifilm Wako Pure Chemical, Ltd.).
  • Temperature: 37°
  • Atmosphere: 5% CO2
  • Volume: 1 ml
  • Storage medium: CELLBANKER 2
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Characterisation tests: Pathogen and stelility test; Comprehensive gene expression analysis; Cancer panel sequencing; Whole exome sequencing; Anticancer drug susceptibility testing
  • Mycoplasma free: Yes
  • Biosafety level: 2

Application Details

  • Application: 3D cell culture, High-throughput screening

Documentation